News & Updates

Endovascular therapy (EVT) in addition to medical therapy appeared to improve outcomes in patients with acute large vessel occlusion (LVO) with large ischaemic core following a stroke, according to results of the RESCUE-Japan LIMIT* trial.

The incidence of engraftment syndrome (ES), a common complication of autologous haematopoietic cell transplantation (HCT), is comparable between melphalan formulations among patients with multiple myeloma and immunoglobulin light chain amyloidosis, reveals a study.

The addition of obinutuzumab, a humanized type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, to a background of standard-of-care (SoC) therapy led to improved renal responses in patients with proliferative lupus nephritis (LN) compared with SoC alone, findings from the phase II NOBILITY trial have shown.

First-line treatment with a combination of nivolumab plus ipilimumab (NIVO + IPI) continues to show long-term survival benefits over sunitinib out to 5 years in patients with advanced clear-cell renal carcinoma (RCC) with sarcomatoid features, according to the CheckMate 214 study presented at GUCS 2022.

Supplementation with oral magnesium for 24 weeks hardly produces any change in arterial stiffness or blood pressure (BP), as do magnesium oxide and magnesium sulphate, as shown in a study.

Clinical oncology pharmacists must deliver patient information on the correct use of capecitabine, manage adverse reactions, and monitor adherence to treatment among patients with gastrointestinal (GI) cancer, suggests a study.